menu
    • menu

    Company profile for AnHeart Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AnHeart Therapeutics (Hangzhou) Co., Ltd. (hereinafter referred to as AHT) was established in November 2018, headquartered in Hangzhou, Zhejiang Province, China, with offices in Beijing, Shanghai and New York City. AHT is dedicated to the development innovative pharmaceutical of significant improvement in human health and quality of life, with a particular focus on innovative drug for unmet clinical needs. Founded by a team...
    AnHeart Therapeutics (Hangzhou) Co., Ltd. (hereinafter referred to as AHT) was established in November 2018, headquartered in Hangzhou, Zhejiang Province, China, with offices in Beijing, Shanghai and New York City. AHT is dedicated to the development innovative pharmaceutical of significant improvement in human health and quality of life, with a particular focus on innovative drug for unmet clinical needs. Founded by a team of experienced experts with extensive global clinical development and registration experience, AHT has attracted professionals with rich experience in multinational pharmaceutical companies and innovative

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AnHeart TherapeuticsChina Flag
    Country
    Country
    China
    Address
    Address
    Room 423, No.1 Qun Building, Hangzhou East Pharmaceutical Port, 291, Fucheng ...
    Telephone
    Telephone
    86571-56263086
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://anhearttherapeutics.com/en/home/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nuvation Bio Completes Acquisition of AnHeart Therapeutics
    Nuvation Bio Completes Acquisition of AnHeart Therapeutics

    10 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240409678961/en

    BUSINESSWIRE
    10 Apr 2024
    Share Share
    Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
    Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

    25 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240325982081/en

    BUSINESSWIRE
    25 Mar 2024
    Share Share
    Innovent and AnHeart Announce the NMPA Has Accepted NDA for Taletrectinib
    Innovent and AnHeart Announce the NMPA Has Accepted NDA for Taletrectinib

    05 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/innovent-and-anheart-therapeutics-announce-the-nmpa-of-china-has-accepted-second-nda-for-taletrectinib-for-first-line-treatment-of-ros1-positive-lung-cancer-302079359.html

    PR NEWSWIRE
    05 Mar 2024
    Share Share
    AnHeart and Innovent Announce NMPA has Accepted Second NDA for Taletrectinib
    AnHeart and Innovent Announce NMPA has Accepted Second NDA for Taletrectinib

    04 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240304715797/en

    BUSINESSWIRE
    04 Mar 2024
    Share Share
    AnHeart and Innovent Announce NMPA Has Granted Taletrectinib Priority Review
    AnHeart and Innovent Announce NMPA Has Granted Taletrectinib Priority Review

    18 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231218218507/en

    BUSINESSWIRE
    18 Dec 2023
    Share Share
    AnHeart Therapeutics and Foundation Medicine Announce Collaboration
    AnHeart Therapeutics and Foundation Medicine Announce Collaboration

    14 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231214960711/en

    BUSINESSWIRE
    14 Dec 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search